Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up

Texto completo
Autor(es):
Mostrar menos -
Moreira, Regina Celia [1] ; Deguti, Marta Mitiko [2] ; Lemos, Marcilio Figueiredo [1] ; Saraceni, Claudia Patara [1] ; Oba, Isabel Takano [1] ; Miranda Spina, Angela Maria [1] ; Nescimento-Lima, Alessandra Stilhano [2] ; Fares, Jorge [3] ; Azevedo, Raymundo Soares [4] ; Gomes-Gouvea, Michele Soares [2] ; Carrilho, Flair Jose [2] ; Rebello Pinho, Joao Renato [2]
Número total de Autores: 12
Afiliação do(s) autor(es):
[1] Inst Adolfo Lutz Registro, Serv Virol, BR-01246902 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Dept Gastroenterol, LIM 07, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Ctr Hemodialise, Sao Paulo - Brazil
[4] Univ Sao Paulo, Fac Med, Dept Patol, LIM 01, Sao Paulo - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: Memórias do Instituto Oswaldo Cruz; v. 105, n. 1, p. 107-108, FEB 2010.
Citações Web of Science: 8
Resumo

The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units. (AU)

Processo FAPESP: 01/11405-4 - Avaliacao dos marcadores sorologicos e estudos de genotipagem da hepatite b em pacientes submetidos a tratamento por hemodialise.
Beneficiário:Regina Célia Moreira
Modalidade de apoio: Auxílio à Pesquisa - Regular